Form 4: Y-mAbs Therapeutics Director David Gill Receives Significant Equity Awards

Y-mAbs Therapeutics, Inc. Director David N. Gill was granted 25,080 restricted stock units and 33,450 employee stock options on June 30, 2025, as part of the company's 2018 Equity Incentive Plan.

Summary

• David N. Gill, a Director of Y-mAbs Therapeutics, Inc. (YMAB), acquired 25,080 shares of common stock in the form of Restricted Stock Units (RSUs) and 33,450 employee stock options on June 30, 2025.
• The RSUs were granted at a price of $0 and represent a contingent right to receive one share of common stock per RSU. They will vest in full on the earlier of the first anniversary of the grant date or the day before the 2026 annual meeting of stockholders, contingent on Mr. Gill's continued service.
• The employee stock options have an exercise price of $4.51 per share and expire on June 30, 2035. These options will vest in equal monthly installments until the first anniversary of the grant date, subject to Mr. Gill's continued service, and become exercisable immediately upon vesting.
• Following these transactions, Mr. Gill beneficially owns 30,905 shares of common stock and 33,450 employee stock options.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is generally positive as it aligns management's interests with shareholders and serves as a retention mechanism. It does not contain any negative news or red flags.

Positives

• Grant of 25,080 Restricted Stock Units (RSUs) to Director David N. Gill, aligning his interests with shareholder value.
• Grant of 33,450 employee stock options with an exercise price of $4.51, providing further incentive for long-term performance.
• The equity awards are subject to continued service, promoting retention of key leadership.

Risks

• The vesting of both RSUs and stock options is contingent on the Reporting Person's continued service to the Issuer, meaning the awards could be forfeited if service ceases before vesting.
• The value of the stock options is dependent on the future market price of Y-mAbs Therapeutics, Inc. common stock exceeding the exercise price of $4.51.

Future Outlook

The document indicates future vesting events for both the RSUs and stock options, contingent on continued service. The RSUs vest on the earlier of the first anniversary of the grant date or the date immediately preceding the 2026 annual meeting of stockholders. The stock options vest in equal monthly installments until the first anniversary of the grant date.

Industry Context

Equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industries, including companies like Y-mAbs Therapeutics, Inc., to align management incentives with long-term shareholder value and to retain key talent. These grants are typically part of a broader compensation strategy aimed at rewarding performance and ensuring leadership commitment in a highly competitive and innovation-driven sector.

Comparison to Industry Standards

• The granting of Restricted Stock Units (RSUs) and stock options as part of director compensation is a common practice across the biotechnology and pharmaceutical sectors, similar to compensation structures seen at companies like BioNTech SE, Moderna, Inc., or Regeneron Pharmaceuticals, Inc., which frequently utilize equity awards to incentivize and retain key personnel.
• The vesting schedules, tied to continued service and specific dates (e.g., one-year anniversary, annual meeting), are typical for such equity grants, reflecting standard corporate governance practices for executive and director compensation.
• The exercise price of $4.51 for the stock options would be compared to the market price of YMAB stock on the grant date to assess if they were granted at-the-money, in-the-money, or out-of-the-money, which is a standard evaluation for option grants.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders, potentially leading to better long-term performance and value creation. Dilution from future share issuance upon RSU vesting and option exercise is a consideration.
• Employees: While specific to a director, such equity grants are part of a broader compensation philosophy that can impact employee morale and retention if similar incentives are offered across the organization.

Next Steps

• Vesting of 25,080 Restricted Stock Units (RSUs) on the earlier of the first anniversary of the grant date (June 30, 2026) or the date immediately preceding the Issuer's annual meeting of stockholders in 2026, subject to continued service.
• Vesting of 33,450 employee stock options in equal monthly installments until the first anniversary of the grant date (June 30, 2026), subject to continued service.
• Potential exercise of stock options by the reporting person upon vesting and before the expiration date of June 30, 2035.

Key Dates

Keywords

Y-mAbs Therapeutics, YMAB, SEC Form 4, Insider Trading, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director Compensation, David N. Gill, Beneficial Ownership